AgeX Therapeutics to Present at Master Investor Show 2019
April 05 2019 - 8:00AM
Business Wire
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a
biotechnology company focused on therapeutics for human aging,
announced today that the company will participate at Master
Investor Show 2019, in association with Fidelity International, on
Saturday, April 6 in London, England.
Details of the company’s participation follow:
Date and venueSaturday, April 6, Business Design Centre,
52 Upper Street, London
11:40-11:50am GMT – Rising Stars StageAgeX’s founder and
CEO, Michael D. West, Ph.D. will deliver a presentation on the
company’s technology and an update on its product development.
4:15-4:45pm – Panel Session: Investing in the Age of
LongevityDr. West and AgeX’s VP, New Technology Discovery,
Aubrey de Grey, Ph.D. will serve on the panel, alongside AgeX’s
Chairman Gregory Bailey, M.D., who also serves as CEO of
Juvenescence, a significant shareholder of AgeX.
Master Investor Show is co-hosted by Jim Mellon, Chairman of
Juvenescence. A copy of Dr. West’s presentation will be made
available on the AgeX website.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform named induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s
delivery technology to stably engraft PureStem cell therapies and
slowly release iTR molecules in the body. AgeX is developing its
core product pipeline for use in the clinic to extend human
healthspan, and is seeking opportunities to form licensing and
partnership agreements around its broad IP estate and proprietary
technology platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of
AgeX’s Annual Report on Form 10-K filed with the Securities and
Exchange Commissions (copies of which may be obtained at
www.sec.gov). Subsequent events and developments may cause these
forward-looking statements to change. AgeX specifically disclaims
any obligation or intention to update or revise these
forward-looking statements as a result of changed events or
circumstances that occur after the date of this release, except as
required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190405005079/en/
Media Contact for AgeX:Bill DouglassGotham Communications,
LLCbill@gothamcomm.com(646) 504-0890
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Apr 2023 to Apr 2024